NasdaqGS - Delayed Quote • USD
United Therapeutics Corporation (UTHR)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 16 | 14 |
| Avg. Estimate | 5.65 | 6.09 | 24.04 | 24.85 |
| Low Estimate | 4.75 | 5.16 | 20.7 | 19.95 |
| High Estimate | 6.53 | 8.74 | 31.76 | 28.74 |
| Year Ago EPS | 4.86 | 5.24 | 19.81 | 24.04 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 15 | 13 |
| Avg. Estimate | 623.97M | 682.57M | 2.7B | 2.83B |
| Low Estimate | 589.7M | 617.53M | 2.47B | 2.47B |
| High Estimate | 687.51M | 990.1M | 3.6B | 3.14B |
| Year Ago Sales | 514.37M | -- | 2.33B | 2.7B |
| Sales Growth (year/est) | 21.30% | -- | 16.00% | 4.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 4.52 | 4.5 | 5.04 | 4.19 |
| EPS Actual | 4.86 | 5.24 | 5.38 | 4.36 |
| Difference | 0.34 | 0.74 | 0.34 | 0.17 |
| Surprise % | 7.50% | 16.40% | 6.70% | 4.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 5.65 | 6.09 | 24.04 | 24.85 |
| 7 Days Ago | 5.65 | 6.09 | 24.04 | 24.85 |
| 30 Days Ago | 5.65 | 6.09 | 24.04 | 24.86 |
| 60 Days Ago | 5.62 | 6.08 | 23.56 | 24.45 |
| 90 Days Ago | 5.57 | 6.1 | 22.07 | 24.46 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | UTHR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 16.30% | -- | -- | 6.50% |
| Next Qtr. | 16.20% | -- | -- | 12.00% |
| Current Year | 21.40% | -- | -- | 5.30% |
| Next Year | 3.40% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 9.70% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 17.67% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Wells Fargo: Overweight to Overweight | 3/7/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 2/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/22/2024 |
| Upgrade | Goldman Sachs: Sell to Neutral | 2/12/2024 |
| Initiated | Leerink Partners: Outperform | 2/5/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 11/2/2023 |
Related Tickers
LQDA Liquidia Corporation
12.53
+1.29%
MNKD MannKind Corporation
4.2300
+1.20%
HALO Halozyme Therapeutics, Inc.
38.57
+0.29%
GMAB Genmab A/S
28.15
+2.51%
HRMY Harmony Biosciences Holdings, Inc.
29.32
+1.35%
ARGX argenx SE
372.80
+1.14%
INSM Insmed Incorporated
24.80
-0.48%
LEGN Legend Biotech Corporation
45.30
+1.98%
JAZZ Jazz Pharmaceuticals plc
109.46
+1.89%
IONS Ionis Pharmaceuticals, Inc.
41.59
-0.60%